Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:32 pm Sale |
2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH |
RA Capital Management, L.P. | 2,866,733 9.400% |
-128,290 (-4.28%) |
Filing History |
| 2025-02-14 6:31 pm Sale |
2024-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN |
RA Capital Management, L.P. | 5,755,577 5.700% |
-2,054,275 (-26.30%) |
Filing History |
| 2025-02-14 6:31 pm Purchase |
2024-12-31 | 13G | Adagio Medical Holdings, Inc. ADGM |
RA Capital Management, L.P. | 1,613,220 9.900% |
275,407 (+20.59%) |
Filing History |
| 2025-02-14 6:30 pm Sale |
2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
RA Capital Management, L.P. | 4,564,867 9.900% |
-533,344 (-10.46%) |
Filing History |
| 2025-02-14 6:29 pm Sale |
2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB |
RA Capital Management, L.P. | 0 0.000% |
-6,809,404 (Position Closed) |
Filing History |
| 2025-02-14 6:28 pm Sale |
2024-12-31 | 13G | Cybin Inc. CYBN |
RA Capital Management, L.P. | 0 0.000% |
-1,529,988 (Position Closed) |
Filing History |
| 2025-02-14 6:28 pm Purchase |
2024-12-31 | 13G | CervoMed Inc. CRVO |
RA Capital Management, L.P. | 916,063 9.900% |
90,690 (+10.99%) |
Filing History |
| 2025-02-14 6:27 pm Sale |
2024-12-31 | 13G | BioAge Labs, Inc. BIOA |
RA Capital Management, L.P. | 1,310,589 3.700% |
-900,000 (-40.71%) |
Filing History |
| 2025-02-14 6:27 pm Sale |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
RA Capital Management, L.P. | 0 0.000% |
-1,999,997 (Position Closed) |
Filing History |
| 2025-02-14 6:26 pm Sale |
2024-12-31 | 13G | Alto Neuroscience, Inc. ANRO |
RA Capital Management, L.P. | 0 0.000% |
-2,075,154 (Position Closed) |
Filing History |
| 2025-02-14 6:25 pm Purchase |
2024-12-31 | 13G | Monopar Therapeutics Inc. MNPR |
RA Capital Management, L.P. | 620,116 9.900% |
108,909 (+21.30%) |
Filing History |
| 2025-02-14 6:24 pm Unchanged |
2024-12-31 | 13G | Zura Bio Limited ZURA |
RA Capital Management, L.P. | 3,217,503 4.900% |
0 (Unchanged) |
Filing History |
| 2025-02-03 5:39 pm Purchase |
2025-01-30 | 13D | 89bio, Inc. ETNB |
RA Capital Management, L.P. | 20,013,733 15.100% |
5,759,435 (+40.40%) |
Filing History |
| 2024-12-30 6:51 pm Purchase |
2024-12-26 | 13D | Vor Biopharma Inc. VOR |
RA Capital Management, L.P. | 39,709,850 31.900% |
16,929,507 (+74.32%) |
Filing History |
| 2024-12-06 5:30 pm Purchase |
2024-11-29 | 13G | Alector, Inc. ALEC |
RA Capital Management, L.P. | 9,695,228 9.900% |
9,695,228 (New Position) |
Filing History |
| 2024-12-05 6:55 pm Purchase |
2024-11-27 | 13G | Kura Oncology, Inc. KURA |
RA Capital Management, L.P. | 4,368,998 5.600% |
4,368,998 (New Position) |
Filing History |
| 2024-11-26 5:32 pm Purchase |
2024-11-26 | 13D | Cidara Therapeutics, Inc. CDTX |
RA Capital Management, L.P. | 1,092,796 9.990% |
389,716 (+55.43%) |
Filing History |
| 2024-11-22 4:12 pm Purchase |
2024-11-15 | 13G | Arcellx, Inc. ACLX |
RA Capital Management, L.P. | 2,787,327 5.200% |
2,787,327 (New Position) |
Filing History |
| 2024-11-18 8:19 pm Unchanged |
2024-11-14 | 13D | 89bio, Inc. ETNB |
RA Capital Management, L.P. | 14,254,298 11.900% |
0 (Unchanged) |
Filing History |
| 2024-11-15 5:05 pm Sale |
2024-11-13 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
RA Capital Management, L.P. | 5,098,211 11.000% |
-103,934 (-2.00%) |
Filing History |